Deregulation of adipokines related to target organ damage on resistant hypertension

Journal of Human Hypertension

Volumn 28, Issue 6, 2014, Pages 388-392

  Sabbatini, A R ^a   Faria, A P ^a   Barbaro, N R ^a   Gordo, W M ^a   Modolo, R G P ^a   Pinho, C ^b   Fontana, V ^a   Moreno, H ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

Author keywords

adipokines; resistant hypertension; target organ damage

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; RESISTIN; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; ORGAN INJURY; PROTEIN BLOOD LEVEL; PULSE WAVE; RESISTANT HYPERTENSION; AGED; ALBUMINURIA; BLOOD; BLOOD ANALYSIS; BRAZIL; COMPARATIVE STUDY; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECTS; DRUG RESISTANCE; ECHOGRAPHY; HYPERTENSION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; STATISTICAL MODEL; VASCULAR RESISTANCE;

ADIPOKINES; ADIPONECTIN; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; BLOOD PRESSURE MONITORING, AMBULATORY; BODY MASS INDEX; BRAZIL; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DRUG RESISTANCE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LEPTIN; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PULSE WAVE ANALYSIS; RESISTIN; STATISTICS, NONPARAMETRIC; VASCULAR RESISTANCE; VASCULAR STIFFNESS;

EID: 84900023265     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.118     Document Type: Article

References (35)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-e526.
2. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334-341.
3. Vlek AL, van der Graaf Y, Spiering W, Algra A, Visseren FL. Cardiovascular events and all-cause mortality by albuminuria and decreased glomerular filtration rate in patients with vascular disease. J Intern Med 2008; 264: 351-360.
4. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-1241.
5. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF et al. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens 2011; 25: 532-538.
6. Quinaglia T, Martins LC, Figueiredo VN, Santos RC, Yugar-Toledo JC, Martin JF et al. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens 2011; 25: 656-664.
7. Fonseca-Alaniz MH, Takada J, Alonso-Vale MI, Lima FB. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr (Rio J) 2007; 83: S192-S203.
8. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007; 49: 1455-1461.
9. Schutte R, Huisman HW, Schutte AE, Malan NT. Leptin is independently associated with systolic blood pressure, pulse pressure and arterial compliance in hypertensive African women with increased adiposity: the POWIRS study. J Hum Hypertens 2005; 19: 535-541.
10. Zhang L, Curhan GC, Forman JP. Plasma resistin levels associate with risk for hypertension among nondiabetic women. J Am Soc Nephrol 2010; 21: 1185-1191.
11. Fang C, Lei J, Zhou SX, Zhang YL, Yuan GY, Wang JF. Association of higher resistin levels with in?ammatory activation and endothelial dysfunction in patients with essential hypertension. Chin Med J (Engl) 2013; 126: 646-649.
12. Youn JC, Kim C, Park S, Lee SH, Kang SM, Choi D et al. Adiponectin and progression of arterial stiffness in hypertensive patients. Int J Cardiol 2011; 163(3): 316-319.
13. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 2004; 13: 236-242.
14. Wannamethee SG, Tchernova J, Whincup P, Lowe GD, Kelly A, Rumley A et al. Plasma leptin: associations with metabolic, in?ammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis 2007; 191: 418-426.
15. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008; 114: 361-374.
16. Kartal O, Inal V, Baysan O, Saglam K. Relationship between serum leptin levels and left ventricular hypertrophy in obese hypertensive patients. Anatol J Cardiol 2008; 8: 342-346.
17. Schutte AE, Huisman HW, Schutte R, van Rooyen JM, Malan L, Fourie CMT et al. Adipokines and cardiometabolic function: How are they interlinked? Regul Peptides 2010; 164: 133-138.
18. de Haro Moraes C, Figueiredo VN, de Faria AP, Barbaro NR, Sabbatini AR, Quinaglia T et al. High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. J Hum Hypertens 2013; 27: 225-230.
19. de Faria APC, Demacq C, Figueiredo VN, Moraes CH, Santos RC, Sabbatini AR et al. Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension. Hypertens Res 2013; 36: 1067-1072.
20. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605.
21. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18(12): 1440-1463.
22. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253.
23. Ehrhart-Bornstein M, Arakelyan K, Krug AW, Scherbaum WA, Bornstein SR. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res 2004; 30: 865-870.
24. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451.
25. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 932-943.
26. Tsioufis C, Dimitriadis K, Chatzis D, Vasiliadou C, Tousoulis D, Papademetriou V et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 2005; 96: 946-951.
27. Tesauro M, Mascali A, Franzese O, Cipriani S, Cardillo C, Di Daniele N. Chronic kidney disease, obesity, and hypertension: the role of leptin and adiponectin. Int J Hypertens 2012; 2012: 943605.
28. Meyer C, Robson D, Rackovsky N, Nadkarni V, Gerich J. Role of the kidney in human leptin metabolism. Am J Physiol 1997; 273: E903-E907.
29. Pladevall M, Williams K, Guyer H, Sadurni J, Falces C, Ribes A et al. The association between leptin and left ventricular hypertrophy: a population-based cross-sectional study. J Hypertens 2003; 21: 1467-1473.
30. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin an adipokine with potent proin?ammatory properties. J Immunol 2005; 174: 5789-5795.
31. Windham BG, Griswold ME, Farasat SM, Ling SM, Carlson O, Egan JM et al. In?uence of leptin, adiponectin, and resistin on the association between abdominal adiposity and arterial stiffness. Am J Hypertens 2010; 23: 501-507.
32. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J et al. Long-term angiotensin II AT(1) receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPAR-gamma. Eur J Pharmacol 2006; 552: 112-122.
33. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Koh Y et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2010; 140: 73-81.
34. Ubaid-Girioli S, Ferreira-Melo SE, Souza LA, Nogueira EA, Yugar-Toledo JC, Coca A et al. Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich) 2007; 9: 770-774.
35. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150: 776-783.